AB202039

Anti-C5a antibody [EPR19699-24]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(3 Publications)

Rabbit Recombinant Monoclonal C5 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 3 publications.

View Alternative Names

CPAMD4, C5, Complement C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4

2 Images

Supplier Data

Immunoprecipitation - Anti-C5a antibody [EPR19699-24] (AB202039)

C5a was immunoprecipitated from 0.35 mg human serum 10μg with ab202039 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab202039 at 1/2000 dilution (0.26 μg/ml). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/10,000 dilution.

Lane 1 : Human serum 10μg.

Lane 2 : ab202039 IP in human serum.

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab202039 in human serum.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 10 seconds.

This antibody recognizes C5a.

All lanes:

Immunoprecipitation - Anti-C5a antibody [EPR19699-24] (ab202039)

false

Supplier Data

Western blot - Anti-C5a antibody [EPR19699-24] (AB202039)

C5 is cleaved into C5α and C5β and this antibody recognizes the C5α. The molecular weight observed is consistent with what has been described in the literature (PMID : 23401592)

All lanes:

Western blot - Anti-C5a antibody [EPR19699-24] (ab202039) at 1/1000 dilution

All lanes:

Human serum at 20 µg

Secondary

All lanes:

Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/1000 dilution

false

Exposure time: 3min

Carrier free

Anti-C5a antibody [EPR19699-24] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR19699-24

Isotype

IgG

Carrier free

Reacts with

Human

Applications

WB, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C5a also known as complement component 5a is a 74-amino acid peptide with a molecular mass of approximately 11 kDa. It is expressed in the blood and is a fragment that forms when the complement system part of the body’s immune response activates. As a potent anaphylatoxin C5a plays a role in mediating inflammation and recruiting white blood cells to an infection site. It interacts with C5a receptors C5aR1 and C5aR2 located on various immune cells including neutrophils monocytes and macrophages.

Biological function summary

C5a functions as part of the complement cascade a complex series of events essential for opsonization cell lysis and inflammation. C5a binds to its receptors initiating cell responses such as chemotaxis increased vascular permeability and release of pro-inflammatory cytokines. These processes help in pathogen clearance making C5a a significant player in innate immunity. C5a exists as part of the larger complement system that includes proteins like C3 and C5 forming an important arm of the body's defense against pathogens.

Pathways

C5a integrates into the complement pathway and the coagulation cascade. It drives actions in the inflammatory response enhancing immune defense by promoting cytokine production and leukocyte migration. Important interactions occur with complement proteins such as C3 and C5b-9 key elements of the terminal complement complex. By influencing these pathways C5a directly contributes to both immune modulation and inflammatory processes.

C5a is linked to conditions such as sepsis and rheumatoid arthritis. In these diseases C5a contributes to excessive inflammation and tissue damage. C5a's interaction with C5aR1 and other receptors like CR1 involved in inflammatory regulation exemplifies its role in advancing disease states. Therapeutically targeting C5a and its receptors remains an active area of research aiming to develop treatments for conditions driven by dysregulated complement activation.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.. C5a anaphylatoxin. Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed : 8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

See full target information C5

style

left-column

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Communications biology 8:879 PubMed40481230

2025

High-fat diet induces pre-eclampsia through dampening cell-autonomous C3 in trophoblasts.

Applications

Unspecified application

Species

Unspecified reactive species

Simeng Zhu,Siyue Chen,Yingzhou Ge,Fangyue Zhou,Kaizhen Su,Congfeng Xu,Yanting Wu,Hefeng Huang

ACS infectious diseases 8:2348-2361 PubMed36219583

2022

α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement Cascade.

Applications

Unspecified application

Species

Unspecified reactive species

Rui Qin,Emma Kurz,Shuhui Chen,Briana Zeck,Luis Chiribogas,Dana Jackson,Alex Herchen,Tyson Attia,Michael Carlock,Amy Rapkiewicz,Dafna Bar-Sagi,Bruce Ritchie,Ted M Ross,Lara K Mahal

Experimental and therapeutic medicine 22:684 PubMed33986849

2021

Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting complement activation and upregulation of miR-499.

Applications

Unspecified application

Species

Unspecified reactive species

Zheng Huang,Yan He,Qing-Jie Li,Hong Wen,Xin-Yue Zhang,Rong-Hui Tu,Guo-Qiang Zhong

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-C5a antibody [EPR19699-24]

Immunoprecipitation - Anti-C5a antibody [EPR19699-24] (AB202039)

Western blot - Anti-C5a antibody [EPR19699-24] (AB202039)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (3)

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Product promise